风险分层:预测局限性前列腺癌主动监测病程的工具?
HAROW研究为前瞻性、非干预性、观察性结局研究,纳入468例接受主动监测的局限性前列腺癌患者,按极低危、低危、中/高危分层,平均随访28.5个月。结果显示三组中止主动监测率分别为25.4%、21.1%和24.4%(P=0.633),后续治疗及延迟手术病理结果无显著差异;中/高危组因患者意愿要求转为侵入性治疗更常见(P<0.05)。
要点
- 极低危、低危、中/高危三组主动监测中止率分别为25.4%、21.1%和24.4%,差异无统计学意义(P=0.633)。
- 极低危和低危组干预主要原因为活检升级和/或前列腺特异性抗原升高,中/高危组主要为患者意愿(P<0.05)。
- 三组后续治疗及延迟手术病理结果无显著差异。
核心结论
- 按风险分层管理的主动监测患者,各组结局无差异,但中/高危组因患者要求转为侵入性治疗更频繁。
研究设计与样本
- HAROW研究为前瞻性、非干预性、观察性结局研究,在社区医疗环境中开展,共纳入468例接受主动监测的局限性前列腺癌患者,平均随访28.5个月。
- 治疗泌尿外科医生每6个月报告临床变量、治疗信息及疾病临床病程。
主要发现
- 468例接受主动监测的患者中,244例分为极低危组、142例分为低危组、82例分为中/高危组。
- 112例中止主动监测,极低危组中止率为25.4%,低危组为21.1%,中/高危组为24.4%(P=0.633)。
- 极低危组和低危组的主要干预原因为活检升级和/或前列腺特异性抗原升高,中/高危组的主要干预原因为患者意愿(P<0.05)。
- 后续治疗及延迟手术后的病理结果无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate a cohort of patients undergoing active surveillance (AS) for localized prostate cancer (PCa) with regard to possible differences in discontinuation rates, subsequent therapies, reasons for intervention and pathological findings after deferred surgery after patient stratification into very-low-risk, low-risk and intermediate-/high-risk PCa groups. PATIENTS AND METHODS: The HAROW study was a non-interventional, observational, outcomes research study on the management of localized PCa in the community setting. A total of 468 patients were prospectively enrolled in the HAROW study, with a mean follow-up of 28.5 months. Treating urologists reported clinical variables, information on therapy and clinical course of disease at 6-month intervals. RESULTS: Of 468 patients under AS, 244 were stratified into very-low-risk, 142 into low-risk and 82 into intermediate-/high-risk groups. Of these patients, 112 discontinued AS. Discontinuation rates were 25.4% in the very-low-risk, 21.1% in the low-risk and 24.4% in the intermediate-/high-risk groups (P = 0.633). The main reasons for intervention were biopsy upgrade and/or prostate-specific antigen elevation in the very-low- and low-risk groups, and patient preference in the intermediate-/high-risk group (P < 0.05). No significant differences were found regarding subsequent therapies and pathological findings after deferred surgery. CONCLUSION: Our results show no differences in the outcome of risk-stratified patients in the specified risk groups managed with AS, while switching to an invasive treatment on the patient's request was more frequent in the intermediate-/high-risk group.
引用
- Herden J, Heidenreich A, Weissbach L, et al. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer? BJU Int. 2016. PMID: 27862832. doi:10.1111/bju.13715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。